RGDFAP: Platelet aggregation inhibitory and profibrinolytic hybrid peptide (RGDF coupled with the carboxy terminal part of α2-antiplasmin) enhances plasminogen 2 binding to platelets

M. Udvardy, D. Schwartzott, K. Jackson, E. Posan, K. Rak, P. A. McKee

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

As published in a recent issue of Blood Coagulation and Fibrinolysis, the hybrid peptide RGDFAP, composed of RGDF (Arg-Gly-Asp-Phe) coupled to a synthetic peptide residue of the carboxy terminal part of antiplasmin (AP26) inhibited platelet activation and augmented plasmin generation and in vitro fibrin clot lysis. This peptide contains an RGD motif which provides linkage to platelet GP IIb-IIIa. The antiplasmin part of the molecule may attach free plasminogen, which in turn increases the amount of platelet surface bound plasminogen, probably yielding enhanced lytic action at the site of thrombus formation. This hypothesis was investigated and confirmed by the results of platelet-plasminogen binding assays, using FITC-labelled antiplasmin antibodies and radioligand binding analysis. Increased platelet-linked plasminogen was detected by a chromogenic method, along with the acceleration of in vitro lysis of platelet-rich clots in the presence of RGDFAP peptide.

Original languageEnglish
Pages (from-to)481-485
Number of pages5
JournalBlood Coagulation and Fibrinolysis
Volume6
Issue number5
Publication statusPublished - 1995

Fingerprint

arginyl-glycyl-aspartyl-phenylalanine
Antifibrinolytic Agents
Plasminogen
Platelet Aggregation
Blood Platelets
Peptides
Platelet Membrane Glycoprotein IIb
Fluorescein-5-isothiocyanate
Fibrinolysin
Platelet Activation
Blood Coagulation
Fibrinolysis
Fibrin
Thrombosis
Arg-Gly-Asp-Phe-Gly-Gly-Gly-Gly-AP26
Antibodies

Keywords

  • Fibrinolysis
  • Platelet aggregation
  • Platelet-bound plasminogen
  • RGD peptides

ASJC Scopus subject areas

  • Hematology

Cite this

RGDFAP : Platelet aggregation inhibitory and profibrinolytic hybrid peptide (RGDF coupled with the carboxy terminal part of α2-antiplasmin) enhances plasminogen 2 binding to platelets. / Udvardy, M.; Schwartzott, D.; Jackson, K.; Posan, E.; Rak, K.; McKee, P. A.

In: Blood Coagulation and Fibrinolysis, Vol. 6, No. 5, 1995, p. 481-485.

Research output: Contribution to journalArticle

@article{3b650c31dae045d99c60af0b6c9b05db,
title = "RGDFAP: Platelet aggregation inhibitory and profibrinolytic hybrid peptide (RGDF coupled with the carboxy terminal part of α2-antiplasmin) enhances plasminogen 2 binding to platelets",
abstract = "As published in a recent issue of Blood Coagulation and Fibrinolysis, the hybrid peptide RGDFAP, composed of RGDF (Arg-Gly-Asp-Phe) coupled to a synthetic peptide residue of the carboxy terminal part of antiplasmin (AP26) inhibited platelet activation and augmented plasmin generation and in vitro fibrin clot lysis. This peptide contains an RGD motif which provides linkage to platelet GP IIb-IIIa. The antiplasmin part of the molecule may attach free plasminogen, which in turn increases the amount of platelet surface bound plasminogen, probably yielding enhanced lytic action at the site of thrombus formation. This hypothesis was investigated and confirmed by the results of platelet-plasminogen binding assays, using FITC-labelled antiplasmin antibodies and radioligand binding analysis. Increased platelet-linked plasminogen was detected by a chromogenic method, along with the acceleration of in vitro lysis of platelet-rich clots in the presence of RGDFAP peptide.",
keywords = "Fibrinolysis, Platelet aggregation, Platelet-bound plasminogen, RGD peptides",
author = "M. Udvardy and D. Schwartzott and K. Jackson and E. Posan and K. Rak and McKee, {P. A.}",
year = "1995",
language = "English",
volume = "6",
pages = "481--485",
journal = "Blood Coagulation and Fibrinolysis",
issn = "0957-5235",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - RGDFAP

T2 - Platelet aggregation inhibitory and profibrinolytic hybrid peptide (RGDF coupled with the carboxy terminal part of α2-antiplasmin) enhances plasminogen 2 binding to platelets

AU - Udvardy, M.

AU - Schwartzott, D.

AU - Jackson, K.

AU - Posan, E.

AU - Rak, K.

AU - McKee, P. A.

PY - 1995

Y1 - 1995

N2 - As published in a recent issue of Blood Coagulation and Fibrinolysis, the hybrid peptide RGDFAP, composed of RGDF (Arg-Gly-Asp-Phe) coupled to a synthetic peptide residue of the carboxy terminal part of antiplasmin (AP26) inhibited platelet activation and augmented plasmin generation and in vitro fibrin clot lysis. This peptide contains an RGD motif which provides linkage to platelet GP IIb-IIIa. The antiplasmin part of the molecule may attach free plasminogen, which in turn increases the amount of platelet surface bound plasminogen, probably yielding enhanced lytic action at the site of thrombus formation. This hypothesis was investigated and confirmed by the results of platelet-plasminogen binding assays, using FITC-labelled antiplasmin antibodies and radioligand binding analysis. Increased platelet-linked plasminogen was detected by a chromogenic method, along with the acceleration of in vitro lysis of platelet-rich clots in the presence of RGDFAP peptide.

AB - As published in a recent issue of Blood Coagulation and Fibrinolysis, the hybrid peptide RGDFAP, composed of RGDF (Arg-Gly-Asp-Phe) coupled to a synthetic peptide residue of the carboxy terminal part of antiplasmin (AP26) inhibited platelet activation and augmented plasmin generation and in vitro fibrin clot lysis. This peptide contains an RGD motif which provides linkage to platelet GP IIb-IIIa. The antiplasmin part of the molecule may attach free plasminogen, which in turn increases the amount of platelet surface bound plasminogen, probably yielding enhanced lytic action at the site of thrombus formation. This hypothesis was investigated and confirmed by the results of platelet-plasminogen binding assays, using FITC-labelled antiplasmin antibodies and radioligand binding analysis. Increased platelet-linked plasminogen was detected by a chromogenic method, along with the acceleration of in vitro lysis of platelet-rich clots in the presence of RGDFAP peptide.

KW - Fibrinolysis

KW - Platelet aggregation

KW - Platelet-bound plasminogen

KW - RGD peptides

UR - http://www.scopus.com/inward/record.url?scp=0029023832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029023832&partnerID=8YFLogxK

M3 - Article

C2 - 8589217

AN - SCOPUS:0029023832

VL - 6

SP - 481

EP - 485

JO - Blood Coagulation and Fibrinolysis

JF - Blood Coagulation and Fibrinolysis

SN - 0957-5235

IS - 5

ER -